BR112018069515A2 - uso de masitinibe para tratamento de uma subpopulação de pacientes com esclerose lateral amiotrófica - Google Patents

uso de masitinibe para tratamento de uma subpopulação de pacientes com esclerose lateral amiotrófica

Info

Publication number
BR112018069515A2
BR112018069515A2 BR112018069515A BR112018069515A BR112018069515A2 BR 112018069515 A2 BR112018069515 A2 BR 112018069515A2 BR 112018069515 A BR112018069515 A BR 112018069515A BR 112018069515 A BR112018069515 A BR 112018069515A BR 112018069515 A2 BR112018069515 A2 BR 112018069515A2
Authority
BR
Brazil
Prior art keywords
lateral sclerosis
amyotrophic lateral
masitinib
patients
subpopulation
Prior art date
Application number
BR112018069515A
Other languages
English (en)
Portuguese (pt)
Inventor
Moussy Alain
mansfield Colin
Kinet Jean-Pierre
Original Assignee
Ab Science
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ab Science filed Critical Ab Science
Publication of BR112018069515A2 publication Critical patent/BR112018069515A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/428—Thiazoles condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
BR112018069515A 2016-03-25 2017-03-24 uso de masitinibe para tratamento de uma subpopulação de pacientes com esclerose lateral amiotrófica BR112018069515A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP16162490 2016-03-25
PCT/EP2017/057134 WO2017162884A1 (en) 2016-03-25 2017-03-24 Use of masitinib for treatment of an amyotrophic lateral sclerosis patient subpopulation

Publications (1)

Publication Number Publication Date
BR112018069515A2 true BR112018069515A2 (pt) 2019-04-16

Family

ID=55637258

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112018069515A BR112018069515A2 (pt) 2016-03-25 2017-03-24 uso de masitinibe para tratamento de uma subpopulação de pacientes com esclerose lateral amiotrófica

Country Status (20)

Country Link
US (1) US10092564B2 (cg-RX-API-DMAC7.html)
EP (1) EP3240538B1 (cg-RX-API-DMAC7.html)
JP (2) JP7250312B2 (cg-RX-API-DMAC7.html)
KR (1) KR102293847B1 (cg-RX-API-DMAC7.html)
CN (1) CN108883108B (cg-RX-API-DMAC7.html)
AU (1) AU2017236177B2 (cg-RX-API-DMAC7.html)
BR (1) BR112018069515A2 (cg-RX-API-DMAC7.html)
CA (1) CA3018635C (cg-RX-API-DMAC7.html)
DK (1) DK3240538T3 (cg-RX-API-DMAC7.html)
EA (1) EA038531B1 (cg-RX-API-DMAC7.html)
ES (1) ES2899929T3 (cg-RX-API-DMAC7.html)
HU (1) HUE057398T2 (cg-RX-API-DMAC7.html)
IL (1) IL261856B (cg-RX-API-DMAC7.html)
MX (1) MX390495B (cg-RX-API-DMAC7.html)
NZ (1) NZ745778A (cg-RX-API-DMAC7.html)
PL (1) PL3240538T3 (cg-RX-API-DMAC7.html)
PT (1) PT3240538T (cg-RX-API-DMAC7.html)
SG (1) SG11201808106YA (cg-RX-API-DMAC7.html)
SI (1) SI3240538T1 (cg-RX-API-DMAC7.html)
WO (1) WO2017162884A1 (cg-RX-API-DMAC7.html)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9925282B2 (en) 2009-01-29 2018-03-27 The General Hospital Corporation Cromolyn derivatives and related methods of imaging and treatment
CN104869993B (zh) 2012-10-25 2019-01-15 通用医疗公司 治疗阿尔茨海默病及相关疾病的组合疗法
US10525005B2 (en) 2013-05-23 2020-01-07 The General Hospital Corporation Cromolyn compositions and methods thereof
AU2014340182B2 (en) 2013-10-22 2019-05-23 The General Hospital Corporation Cromolyn derivatives and related methods of imaging and treatment
US20190240194A1 (en) * 2016-08-31 2019-08-08 The General Hospital Corporation Macrophages/microglia in neuro-inflammation associated with neurodegenerative diseases
MX379222B (es) 2016-11-25 2025-03-10 Genuv Inc Composición para promover la diferenciación y protección de células madre neurales y método para inducir la regeneración neural usando las mismas.
CA3057040A1 (en) * 2017-03-28 2018-10-04 Novartis Ag New methods for the treatment of multiple sclerosis
BR112019025346A2 (pt) * 2017-05-30 2020-06-30 Deciphera Pharmaceuticals, Inc. uso de 1-[4-bromo-5-[1-etil-7-(metilamino)-2-oxo-1,2-dihidro-1,6-naftiridin-3-il]-2-fluorofenil]-3-fenilureia e análogos para o tratamento de cânceres associados a anormalidades genéticas no receptor alfa do fator de crescimento derivado de plaquetas
US11692029B2 (en) 2018-03-05 2023-07-04 The Schepens Eye Research Institute, Inc. Therapy for glaucoma and optic neuropathy by targeting colony stimulating factors
KR20210071943A (ko) 2018-07-02 2021-06-16 더 제너럴 하스피탈 코포레이션 크로몰린 소듐 및 α-락토스의 분말화된 제형
US12383528B2 (en) 2018-12-10 2025-08-12 The General Hospital Corporation Cromolyn esters and uses thereof
CN112618717A (zh) * 2019-09-24 2021-04-09 北京大学深圳研究生院 Btk抑制剂用于治疗肌萎缩侧索硬化症的用途
FI4084779T3 (fi) * 2019-12-30 2024-12-16 Deciphera Pharmaceuticals Llc 1-(4-bromi-5-(1-etyyli-7-(metyyliamino)-2-okso-1,2-dihydro-1,6-naftyridin-3-yyli)-2-fluorifenyyli)-3-fenyyliurean koostumuksia
WO2021207060A1 (en) 2020-04-06 2021-10-14 The General Hospital Corporation Methods of treatment of coronavirus-induced inflammation conditions
US12612391B2 (en) 2020-12-28 2026-04-28 The General Hospital Corporation Cromolyn derivatives and uses thereof
US20250129067A1 (en) * 2021-11-08 2025-04-24 Progentos Therapeutics, Inc. Platelet-derived growth factor receptor (pdgfr) alpha inhibitors and uses thereof
WO2025113494A1 (zh) * 2023-11-27 2025-06-05 浙江径科医药有限公司 多环类化合物及其应用
WO2026015576A1 (en) * 2024-07-09 2026-01-15 PhenoNet, Inc. Methods and systems for treatment of neurodegenerative disease and uses thereof

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW225528B (cg-RX-API-DMAC7.html) 1992-04-03 1994-06-21 Ciba Geigy Ag
CO4940418A1 (es) 1997-07-18 2000-07-24 Novartis Ag Modificacion de cristal de un derivado de n-fenil-2- pirimidinamina, procesos para su fabricacion y su uso
US8450302B2 (en) 2002-08-02 2013-05-28 Ab Science 2-(3-aminoaryl) amino-4-aryl-thiazoles and their use as c-kit inhibitors
MXPA05001277A (es) 2002-08-02 2005-10-06 Ab Science 2-(3-aminoaril)amino-4-aril-tiazoles y su uso como inhibidores del c-kit.
HRP20110709T1 (hr) 2007-02-13 2011-11-30 Ab Science Postupak sinteze spojeva 2-aminotioazola kao inhibitora kinaza
TW201204360A (en) 2010-04-20 2012-02-01 Ab Science Treatment of multiple sclerosis with MASITINIB
CN109316480A (zh) 2011-07-13 2019-02-12 赛特凯恩蒂克公司 组合als疗法
AU2013326463B2 (en) * 2012-10-04 2018-01-18 Ab Science Use of masitinib for treatment of cancer in patient subpopulations identified using predictor factors
EP2970317A4 (en) * 2013-03-15 2016-11-02 Dana Farber Cancer Inst Inc PYRIMIDODIAZEPINONE COMPOUNDS AND METHOD FOR THE TREATMENT OF DISEASES
US20160263110A1 (en) * 2013-11-04 2016-09-15 Ab Science Use of masitinib for treatment of amyotrophic lateral sclerosis

Also Published As

Publication number Publication date
EP3240538A1 (en) 2017-11-08
NZ745778A (en) 2022-07-01
WO2017162884A1 (en) 2017-09-28
US10092564B2 (en) 2018-10-09
CN108883108B (zh) 2021-08-06
CA3018635A1 (en) 2017-09-28
JP2019515884A (ja) 2019-06-13
IL261856B (en) 2022-04-01
MX2018011349A (es) 2019-02-07
CA3018635C (en) 2023-09-26
AU2017236177A1 (en) 2018-09-20
MX390495B (es) 2025-03-20
EA038531B1 (ru) 2021-09-10
PL3240538T3 (pl) 2022-01-31
SG11201808106YA (en) 2018-10-30
DK3240538T3 (da) 2021-12-06
US20180117037A1 (en) 2018-05-03
IL261856A (en) 2018-10-31
EA201800499A1 (ru) 2019-03-29
CN108883108A (zh) 2018-11-23
KR20180125966A (ko) 2018-11-26
PT3240538T (pt) 2021-12-07
EP3240538B1 (en) 2021-09-29
ES2899929T3 (es) 2022-03-15
SI3240538T1 (sl) 2022-02-28
JP7250312B2 (ja) 2023-04-03
HUE057398T2 (hu) 2022-05-28
KR102293847B1 (ko) 2021-08-26
AU2017236177B2 (en) 2022-03-31
JP2022037132A (ja) 2022-03-08

Similar Documents

Publication Publication Date Title
MX390495B (es) Uso de masitinib para el tratamiento de una subpoblación de pacientes con esclerosis lateral amiotrófica.
ECSP20069416A (es) Tratamiento de la hidradenitis supurativa mediante el uso de inhibidores de jak
BR112015020302A2 (pt) derivado de pirazol
BR112015026006A2 (pt) métodos para o tratamento de câncer com o uso de terapia de combinação com inibidor de cinase tor
MX391850B (es) Compuestos para usarse en el tratamiento o mejoramiento de la enfermedad de huntington
UY37363A (es) Sulfonilureas y compuestos relacionados y sus usos
CR20170563A (es) Compuestos de benzoxacepina oxazolidinona y métodos de uso.
BR112018008966A2 (pt) compostos inibidores de jak quinase para o tratamento de doença respiratória
BR112016029041A8 (pt) uso de um inibidor de glutaminase, composição farmacêutica e kit farmacêutico
MX2016007111A (es) Inhibidores de tirosina quinasa de bruton.
BR112015026247A2 (pt) métodos para o tratamento de câncer com o uso de terapia combinada com inibidor de cinase tor
MX2015014512A (es) Composicion farmaceutica, metodos para tratamiento y sus usos.
BR112015026721A2 (pt) derivados de 3-(2-aminopirimidin-4-il)-5-(3-hidroxipropinil)-1h-pirrolo[2,3-c]piridina como inibidores de nik para o tratamento de câncer
AR092899A1 (es) Uso de masitinib para el tratamiento del cancer en subpoblaciones de pacientes identificados que utilizan factores de prediccion
BR112018014675A2 (pt) novos derivados de cianoindolina substituída como inibidores de nik
BR112015022514A2 (pt) composições que compreendem selênio e uso das mesmas para o tratamento e prevenção de doença ou condições associadas à disfunção mitocondrial
GT201600027A (es) Inhibidores de rorc2 y sus métodos de uso
CL2015002346A1 (es) Estra-1,3,5(10),16-tetraeno-3-carboxamidas para la inhibicion de la 17b-hidroxiesteroide deshidrogenasa (akr1 c3)
PH12016502353A1 (en) Pharmaceutical composition
CO2022000270A2 (es) Inhibidores de enzimas
BR112017016428A2 (pt) ?composto ou sal farmaceuticamente aceitável, composição farmacêutica, uso de um composto ou sal farmaceuticamente aceitável, e, método para tratamento de um distúrbio hiperproliferativo maligno, de uma condição metabólica associada à obesidade, de um distúrbio autoimune ou de um distúrbio inflamatório?
BR112017028048A2 (pt) drospirenona como o único ingrediente contraceptivo para uso
TW201613577A (en) Pharmaceutical combinations
CL2022001736A1 (es) Nuevos compuestos farmacéuticos
BR112017021589A2 (pt) métodos para o tratamento de transtornos cardiovasculares

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI N? 10196/2001, QUE MODIFICOU A LEI N? 9279/96, A CONCESS?O DA PATENTE EST? CONDICIONADA ? ANU?NCIA PR?VIA DA ANVISA. CONSIDERANDO A APROVA??O DOS TERMOS DO PARECER N? 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL N? 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVID?NCIAS CAB?VEIS.

B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B06I Publication of requirement cancelled [chapter 6.9 patent gazette]

Free format text: ANULADA A PUBLICACAO CODIGO 6.6.1 NA RPI NO 2631 DE 08/06/2021 POR TER SIDO INDEVIDA.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06W Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette]
B350 Update of information on the portal [chapter 15.35 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]
B12B Appeal against refusal [chapter 12.2 patent gazette]